A wearable device for treating eye diseases

Abstract

The present invention discloses a wearable device for treating eye diseases. The nasal root and trochlear nerve stimulation unit is an electric pulse generating device that outputs an electric stimulation signal. The ethmoid sinus and turbinate heat auxiliary unit overlaps or partially overlaps with the nasal root and trochlear nerve stimulation unit, and includes a heat-conducting component. The vibration unit outputs vibrations of a preset frequency and amplitude. The bending hinge unit is adapted according to the width and curvature of the user's nose. The power manager in the power management unit manages the charging and discharging of the rechargeable battery and the energy recovery. The wireless signal transmission unit is distributed on the periphery of the bending hinge unit, receives program-controlled parameters, and can receive remote commands, including opening or closing, parameter control, mode configuration, program air upgrade, and power acquisition. The present invention uses wearable surface electrical stimulation technology to apply electric pulses to the nerves at the nasal root and trochlear nerves to relieve pain in the back of the eyeball, blurred vision, and symptoms of dry eyes due to dehydration.

Description

Technical Field

[0001] The present invention belongs to the field of nerve stimulation, and in particular to a wearable device for treating eye diseases. Background Art

[0002] Pain in the back of the eyeball and blurred vision are common in diseases such as glaucoma and keratitis. Glaucoma can be caused by congenital or acquired reasons, which block the flow of aqueous humor in the eye, causing increased intraocular pressure, usually manifested as decreased vision, eye pain, eye congestion, etc. Treatment methods include drug therapy, laser therapy and surgical treatment. Eye drops can be used to reduce intraocular pressure. If the effect is not good, laser treatment or surgery can be considered, but both laser treatment and surgical treatment have certain trauma risks.

[0003] Dry eye, also known as keratoconjunctivitis sicca, is a common eye disease. Due to insufficient tear secretion or excessive evaporation, any abnormality in the amount of tears, the quality of tears, and the natural fluidity of tears will cause tear film instability and / or ocular surface damage, leading to eye discomfort and visual dysfunction. Patients often experience symptoms such as eye fatigue, foreign body sensation, and dryness. This type of disease is called dry eye. Clinically, it is divided into the following categories according to the cause:

[0004] Aqueous deficiency dry eye: caused by the inadequate tear secretion function of the lacrimal gland, such as congenital alacrimation; mucin deficiency dry eye: caused by lack of mucin secretion, such as dry eye caused by Stevens-Johnson syndrome, ocular pemphigoid, trachoma, etc.; lipid deficiency dry eye: caused by meibomian gland dysfunction; mixed dry eye: the most common dry eye in clinical practice, which is caused by two or more of the above causes.

[0005] Dry eyes often affect both eyes, and patients usually feel eye fatigue, foreign body sensation, dryness, and some patients also experience eye burning, soreness, redness, eye pain, photophobia, etc. Dry eyes only slightly affect vision in the early stage, but if the disease continues to progress, it can develop into corneal damage, at which point patients often experience significantly aggravated and unbearable eye pain; in the late stage, corneal ulcers, perforations, or secondary infections may occur, and scars may also form, seriously affecting the patient's vision.

[0006] The FDA has approved the TrueTear intranasal nerve stimulation product for the relief and treatment of aqueous-deficient dry eyes. This therapy does not contain drugs or eye drops, can effectively promote tear production, and can restore the ocular surface to a normal physiological state without eye drops or surgery. It is suitable for most patients with insufficient tear secretion, but continuous use of TrueTear to stimulate the nasal cavity may cause damage to the nasal mucosal tissue. In addition, the safety and effectiveness of the device in pregnant women, patients under 22 years old, patients with nasal or sinus surgery or major trauma, severe nasal airway obstruction or polyps, active and severe systemic or seasonal allergies, rhinitis or sinusitis requiring treatment, untreated intranasal infections, disabling arthritis or neuropathy, severe dexterity dysfunction or limited motor coordination have not been verified. Summary of the invention

[0007] In order to help more patients with posterior eye pain, blurred vision and aqueous-deficient dry eye to solve the problem of visual dysfunction, the technical solution of the present invention is as follows: a wearable device for treating eye diseases, characterized in that it includes a nasal root and trochlear nerve stimulation unit, an ethmoid sinus and turbinate thermal auxiliary unit, a vibration unit, a bending hinge unit, a power management unit and a wireless signal transmission unit, wherein:

[0008] The nasal root and trochlear nerve stimulation units are provided with at least two groups, which are electric pulse generating devices that output electric stimulation signals, and the surface material is conductive gel;

[0009] The ethmoid sinus and turbinate heat auxiliary units are provided with at least two groups, the positions of which overlap or partially overlap with the nasion and trochlear nerve stimulation units, and include heat-conducting components;

[0010] The vibration units are provided with at least two groups, outputting vibrations with preset frequencies and vibration amplitudes;

[0011] The bending hinge unit is arranged at the central position of the entire wearable device, and the bending hinge unit can be adapted according to the width and curvature of the user's nose;

[0012] The power management unit includes a power manager and a rechargeable battery, and the power manager manages the charging and discharging of the rechargeable battery, generates the potential required for the stimulation unit to work, and manages energy recovery;

[0013] The wireless signal transmission unit is distributed around the bending hinge unit, receives program-controlled parameters, and can receive remote commands, including turning on or off, parameter adjustment, mode configuration, program air upgrade, and power acquisition.

[0014] Preferably, the high-voltage power supply in the nasal root and trochlear nerve stimulation unit is boosted from a 3V DC low voltage to a 30V pulsating voltage through a variable PWM controlled LC, and then boosted to 100V and above through a backup voltage circuit formed by cascaded diodes and capacitors. The front and rear stages of the high-voltage power supply circuit are electrically isolated to perform energy and signal isolation transmission, and have electrical isolation characteristics of 3000V and above.

[0015] Preferably, the nasion and trochlear nerve stimulation unit generates 2K-10K medium frequency carrier electrical pulses modulated at a low frequency of 1-200 Hz, and the modulated pulses are symmetrical in the initial state, asymmetrical in the intermediate state, and symmetrical in the final state.

[0016] Preferably, the stimulation and regulation method of the nasion and trochlear nerve stimulation unit is:

[0017] StimAlg=t1*A1+t2*A2*A3*F1*het+t3*A4*A5*F2*vib+t4*A6, t1: time of the first stimulation stage, t2: time of the first asymmetric period, which is the stage of merging stimulation and thermal assistance, t3: time of the second asymmetric period, which is the stage of merging stimulation and vibration, t4: time of the second stimulation stage, A1: stimulation amplitude during t1, A2: amplitude higher than the preset value during t2, A3: amplitude lower than the preset value during t2, A4: amplitude lower than the preset value during t3, A5: amplitude higher than the preset value during t3, A6: stimulation amplitude during t4, F1: asymmetric coefficient of the first stimulation intensity, F2: asymmetric coefficient of the second stimulation intensity, het: thermal assistance coefficient, vib: vibration coefficient, vibration coefficient vib∝(fv,av), fv is the vibration frequency, av is the vibration amplitude.

[0018] The stimulation and control method of the nasal root and trochlear nerve stimulation unit is divided into four stages: t1, t2, t3, and t4.

[0019] In the t1 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t1 treatment stage, the treatment pulse amplitude returns to zero;

[0020] In the t2 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is greater than the positive pulse amplitude. The thermal auxiliary function can be set in the t2 treatment stage, and the thermal auxiliary intensity is controlled by the proportional coefficient;

[0021] In the t3 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is smaller than the positive pulse amplitude. The vibration function can be set in the t3 treatment stage, and the vibration intensity is related to the vibration frequency and vibration amplitude;

[0022] In the t4 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t4 treatment stage, the treatment pulse amplitude returns to zero.

[0023] Preferably, the ethmoid sinus and turbinate thermal auxiliary unit comprises a flexible carbon nanotube film, a thin copper sheet and a thermal insulation layer which are arranged in sequence, wherein the flexible carbon nanotube film is adjacent to the nasal root and trochlear nerve stimulation unit.

[0024] Preferably, the vibration unit includes a transverse linear motor or a micro piezoelectric vibration piece or a mechanical vibration motor.

[0025] Preferably, the vibration frequency of the vibration unit is 10-60 Hz, and the vibration stroke is 0.1 mm-1 mm.

[0026] Preferably, the bending hinge unit includes a first chain shaft, a second chain shaft, a third chain shaft, a micro-chain rod, a horizontal axis limit point and a torque spring, wherein the first chain shaft and the second chain shaft are arranged at intervals, the horizontal axis limit point is set on the third chain shaft, the torque area is an area where a torque spring is provided, and torque springs are distributed on the first chain shaft and the second chain shaft in the torque area, the first chain shaft and the second chain shaft drive the torque spring to generate a torque distribution, and the torque distribution is different according to the different activity angles of different parts of the chain shaft, and once the torque is generated, the current torque value will be maintained to maintain the deformation state of the torque spring, the torque springs in the first chain shaft and the second chain shaft drive the third chain shaft to generate a bulge angle, and the front and rear adjacent third chain shafts overlap to form a bulge, and the horizontal axis limit point on the third chain shaft touches the second chain shaft after the third chain shaft reversely moves to a preset stroke and can no longer move, and the bending hinge unit is prevented from reverse bending through the horizontal axis limit point, that is, it cannot form a concave shape.

[0027] The beneficial effects of the present invention include at least: a wearable technology for treating eye diseases proposed by the present invention, through a "Band-Aid"-shaped device, pressing the electrode placed on the side of the nose can generate a low-frequency modulated medium-frequency carrier electric pulse, which can be combined with the vibration percussion effect to non-invasively penetrate the tissue at the root of the nose and penetrate into the ethmoid sinus, inferior trochlear nerve, external nasal branch of the anterior ethmoid nerve and nasolacrimal duct. After the action, it can improve the pain in the back of the eyeball and blurred vision caused by trochlear nerve injury, and promote the lacrimal gland to secrete tears to achieve effective relief of the symptoms of dry eyes due to lack of water. The thermal auxiliary device is distributed in the stimulation unit area. The thermal auxiliary ethmoid sinus and turbinate area can promote the activity of the lacrimal gland, and at the same time promote the secretion of blocked oil, relieve complex dry eye symptoms, improve the use effect, and improve the treatment efficiency. The device is lightweight and compact, and is easy to wear and use. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 A schematic diagram of the bottom structure of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0029] Figure 2 A schematic diagram of the surface structure of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0030] Figure 3 A schematic diagram of the three-dimensional structure of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0031] Figure 4 A schematic diagram of wearing a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0032] Figure 5 A timing diagram of a stimulation control method for a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0033] Figure 6 This is a schematic diagram of the structure of the ethmoid sinus and turbinate thermal auxiliary unit of the wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0034] Figure 7 A schematic top view of a bending hinge unit of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0035] Figure 8 A bottom view schematically shows a bending hinge unit of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0036] Fig. 9 A schematic side view of a bending hinge unit of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0037] Fig.10 It is a schematic diagram of an enlarged structure of a bending hinge unit of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0038] Fig.11 A schematic diagram of a bending hinge unit of a wearable device for treating eye diseases according to a specific embodiment of the present invention;

[0039] Fig.12 This is a schematic diagram of the high-voltage power supply circuit structure of the bending hinge unit nasal root and trochlear nerve stimulation unit of the wearable device for treating eye diseases according to a specific embodiment of the present invention. DETAILED DESCRIPTION

[0040] The preferred embodiments of the present invention will be described in detail below with reference to the accompanying drawings.

[0041] See also Figure 1-Figure 4 A wearable device for treating eye diseases includes a nasal root and trochlear nerve stimulation unit 10, an ethmoid sinus and turbinate heat assist unit 20, a vibration unit 30, a bending hinge unit 40, a power management unit 50 and a wireless signal transmission unit 60.

[0042] The nasal root and trochlear nerve stimulation unit 10 is an electric pulse generating device, see Fig.12 In this unit, the high-voltage power supply is boosted from a 3V DC low voltage to a 30V pulsating voltage through a variable PWM control LC, and then boosted to 100V and above through a backup voltage circuit formed by a cascaded diode and capacitor. The front and rear stages of the high-voltage power supply circuit are electrically isolated, and have electrical isolation characteristics of 3000V and above. The A1 area is energy isolation, and the A2 area is signal isolation. The A2 area can be isolated by optical linear control or by micro-coil electromagnetic isolation; the high-voltage ends V1, V2, and V3 are of different voltage levels and can be adjusted according to the load size and the voltage requirements on the high-voltage side. They can be linearly fed forward to the PWM control end through the selection switch and the negative feedback link, and the negative Feedback correction of S1 and S2 frequency and duty cycle to achieve high-voltage side adjustment, the advantage of this is that the pulsating stimulation output only needs high voltage at the moment of stimulation output, the boost conversion time is shorter, the variable PWM control boost circuit and the 3000V isolation characteristic circuit can be very small, which is convenient for wearable device integration and application, and can avoid the problem of large volume of traditional transformer structure or inability to achieve energy and signal isolation of front and back stages at the same time. Traditional Boost boost generates constant high voltage during the entire working period, with high power consumption. Some circuits still have the problem of long boost stability establishment time and high power consumption by enabling switch control of Boost circuit. In addition, traditional isolation devices, such as transformers, are only used for "energy (electricity)" transmission before and after isolation, and some isolation chips are only used for "signals (low-voltage small signals, no power)" of front and back stages. What we pre-express here is that we can take into account the above, and realize both power transmission and signal isolation transmission. The nasal root and trochlear nerve stimulation unit 10 can generate 2K-10K medium frequency carrier electric pulses with a low frequency modulation of 1-200Hz. The modulated pulses are symmetrical in the initial state, asymmetrical in the middle state, and symmetrical in the final state. The electric pulses penetrate the tissues at the nasal root and enter the ethmoid sinus, inferior trochlear nerve, external nasal branch of the anterior ethmoid nerve and nasolacrimal duct. After the action, it can promote the lacrimal gland to secrete tears to effectively relieve the symptoms of dry eyes caused by dehydration and the pain in the back of the eyeball and blurred vision caused by trochlear nerve damage. There is a stimulation electrode on each side of the unit. The electrode polarity is changeable. The stimulation electrode is a replaceable conductive gel medium and can be flexibly replaced before and after use.

[0043] See also Figure 5 , the stimulation regulation method is,

[0044] StimAlg=t1*A1+t2*A2*A3*F1*het+t3*A4*A5*F2*vib+t4*A6, t1: time of the first stimulation stage, t2: time of the first asymmetric period, which is the stage of merging stimulation and thermal assistance, t3: time of the second asymmetric period, which is the stage of merging stimulation and vibration, t4: time of the second stimulation stage, A1: stimulation amplitude during t1, A2: amplitude higher than the preset value during t2, A3: amplitude lower than the preset value during t2, A4: amplitude lower than the preset value during t3, A5: amplitude higher than the preset value during t3, A6: stimulation amplitude during t4, F1: asymmetric coefficient of the first stimulation intensity, F2: asymmetric coefficient of the second stimulation intensity, het: thermal assistance coefficient, vib: vibration coefficient, vibration coefficient vib∝(fv,av), fv is the vibration frequency, av is the vibration amplitude.

[0045] The stimulation and control method of the nasal root and trochlear nerve stimulation unit is divided into four stages: t1, t2, t3, and t4.

[0046] In the t1 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t1 treatment stage, the treatment pulse amplitude returns to zero;

[0047] In the t2 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is greater than the positive pulse amplitude. The thermal auxiliary function can be set in the t2 treatment stage, and the thermal auxiliary intensity is controlled by the proportional coefficient;

[0048] In the t3 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is smaller than the positive pulse amplitude. The vibration function can be set in the t3 treatment stage, and the vibration intensity is related to the vibration frequency and vibration amplitude;

[0049] In the t4 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t4 treatment stage, the treatment pulse amplitude returns to zero.

[0050] See also Figure 6 The ethmoid sinus and turbinate thermal assistance unit 20 is integrated in the wearable device. The thermal assistance device is distributed in the stimulation unit area and is in the inner layer of the device. It is a flexible carbon nanotube film 21 with free plasticity. The upper surface of the film 21 is connected to the stimulation unit, and the back of the film 21 is connected to the thin copper sheet 22 for thermal balance of the electrode area. The upper limit of the thermal assistance temperature is 45°C. The back side of the thin copper sheet 22 is covered with a thermal insulation layer 23. The thermal assistance of the ethmoid sinus and turbinate area by this unit can promote the activity of the lacrimal glands, and at the same time promote the secretion of blocked oil and relieve complex dry eye symptoms; the unit defaults to working in the intermediate asymmetric period of the stimulation unit, that is, the first asymmetric period t2. The thermal assistance is stopped after the first asymmetric period t2 ends. The thermal assistance and nasal root stimulation unit can be freely selected by the user to start simultaneously or selectively.

[0051] The vibration unit 30 is integrated in the wearable device and is a transverse linear motor. It can also be a micro piezoelectric vibration piece or a mechanical vibration motor device, etc. The vibration frequency is 10-60Hz and the vibration stroke is 0.1mm-1mm. It is located in the inner layer of the device and is used to produce a tapping effect and vibration feedback to the user. By tapping the tissue at a specific frequency and vibration amplitude, the viscoelasticity and thixotropic properties of the tissue are changed, and the human-computer interaction characteristics during treatment are enhanced. The unit is started in the intermediate asymmetric period of the stimulation unit (i.e., the second asymmetric period t3), and the vibration stops at the end of the second asymmetric period t3. The specific vibration frequency can cover the root of the nose, nasolacrimal duct, and turbinate area, relieve the pain in the back of the eyeball and blurred vision caused by trochlear nerve damage, promote glandular secretion, and relieve dry eye symptoms.

[0052] See also Figure 4 , is a schematic diagram of the user wearing it, with a curved hinge unit 40 in the middle that fits the bridge of the nose, and a group of nasal root and trochlear nerve stimulation units 10, ethmoid sinus and turbinate thermal auxiliary units 20 and vibration units 30 are arranged on each side.

[0053] See also Figure 7-Figure 11The bending hinge unit 40 is composed of a first chain shaft 41, a second chain shaft 42, a third chain shaft 43, a micro chain rod 45, a horizontal axis limit point 46, and a torque spring 44. The first chain shaft 41 and the second chain shaft 42 are arranged at intervals. Torque springs 44 are distributed on the first chain shaft 41 and the second chain shaft 42 of the torque area 400. The torque spring 44 is arranged on the periphery of the micro chain rod 45. The micro chain rod 45 is arranged at the first chain shaft 41 and the second chain shaft 42. A horizontal axis limit point 46 is provided on the third chain shaft 43. The first chain shaft 41 and the second chain shaft 42 drive the torque spring 44 to generate a torque distribution, which is determined by the different activity angles of different parts of the chain shaft. Once the torque is generated, the current torque value will be maintained to maintain the spring deformation state. The first chain shaft 41 and The torque spring 44 in the second chain shaft 42 drives the third chain shaft 43 to generate a bulge angle, and the front and rear of the third chain shaft 43 will overlap to form a bulge. The above structure constitutes a "micro-joint" structure, which is characterized by being able to form a bulge or a horizontal shape. If it is necessary to cancel the torque effect at the first chain shaft 41 and the second chain shaft 42, it is necessary to manually restore the third chain shaft 43 to a horizontal state, so that the torque spring 44 at the first chain shaft 41 and the second chain shaft 42 can be restored to a free state. In the free state, the torque spring 44 is no longer subjected to force. A horizontal axis limit point 46 is provided on the third chain shaft 43. After the chain shaft moves in the reverse direction to a specified stroke, the limit point will touch the second chain shaft 42 and can no longer move. The limit point can prevent the hinge structure from bending in the reverse direction, that is, it cannot form a concave shape. In view of the expected application site, the bridge of the nose is a raised structure used to connect the left and right electrodes of the wearable therapeutic device. The hinge acts as a bridge and is shaped like a "Band-Aid". The hinge can be freely adapted according to the width and curvature of the user's nose. After the match is appropriate, the user presses the electrode on the side of the nose to make it effectively contact the nose. During the application, the hinge can maintain the bending force to ensure the fit and clamping with the nose. After the treatment, the hinge can be restored to a straight state for subsequent use.

[0054] The power management unit 50 is used to manage the charging, discharging and energy recovery of the rechargeable battery in the neural stimulation device, and at the same time generate the potential required for the stimulation unit to work. The energy recovery part converts the additional energy generated by the thermal auxiliary unit 20 into battery energy storage through thermosensitive piezoelectric materials, thereby improving the battery energy utilization efficiency. After the treatment device is used, it can be charged through the magnetic charging cabin. The next time it is used, just open the magnetic charging cabin cover to take out the treatment device for use.

[0055] The wireless signal transmission unit 60 is distributed around the bending hinge. A radio frequency transmission antenna designed based on the communication requirements of the human body area establishes a wireless transmission link with an external programmable App, which is used to send the programmable App parameters to the dry eye treatment device. The user can use the App to turn the treatment device on or off, adjust parameters, configure modes, upgrade programs over the air, and obtain power.

[0056] Place the wearable device for treating eye diseases at the root of the nose, adjust the curvature of the torque area 400 in the bending hinge unit 40, so that the torque spring 44 on the first chain axis 41 and the second chain axis 42 of the torque area 400 generates a torque distribution. The torque enables the wearable device to effectively contact and fix the user's nose. The torque area 400 can be freely adapted according to the width and curvature of the user's nose. After the match is appropriate, the user presses the electrode on the side of the nose to make it effectively contact with the nose. During the application, the hinge can maintain the bending force to ensure the fit and clamping with the nose. After the treatment is over, the hinge can be restored to a straight state for subsequent use. Turn on the treatment device, and the wireless signal transmission unit is turned on for 60 minutes. Arranged on the periphery of the bending hinge, the program-controlled App will establish a communication link with the wearable device. The user can choose to turn on the nasal root and trochlear nerve stimulation unit 10 and set relevant treatment parameters by operating the App. The high-voltage power supply in the unit is boosted from a 3V DC low voltage to a 30V pulsating voltage through PWM regulation LC, and then boosted to 100V and above through a backup voltage circuit composed of cascaded diodes and capacitors. The front and rear stages of the high-voltage power supply circuit are electrically isolated, and have electrical isolation characteristics of 3000V and above. Area A1 is energy isolation, and area A2 is signal isolation, of which area A2 can be isolated by optical linear regulation or by micro-coil electromagnetic isolation; the high-voltage ends V1, V2, and V3 are not At the same voltage level, it can be adjusted according to the load size and the voltage demand on the high-voltage side. It can be linearly fed forward to the PWM control end through the selection switch and the negative feedback link. The negative feedback corrects the frequency and duty cycle of S1 and S2 to achieve high-voltage side adjustment. The advantage of this is that the pulsating stimulation output only requires high voltage at the moment of stimulation output, the boost conversion time is shorter, and the volume of the boost circuit and the 3000V isolation characteristic circuit can be very small, which is convenient for wearable device integration and application. At the same time, it can avoid the problem that the traditional transformer structure is large in volume or cannot simultaneously achieve the energy and signal isolation of the front and rear stages, and turn on or off the ethmoid sinus and turbinate thermal auxiliary unit 20. The unit defaults to working in the intermediate state asymmetric period of the stimulation unit (the first asymmetric period t2), heat assistance is stopped after the first asymmetric period t2, the heat assistance and the nasal root stimulation unit can be freely selected by the user to start simultaneously or selectively, turn on or off the vibration unit 30, which is started in the intermediate asymmetric period of the stimulation unit (the second asymmetric period t3), and the vibration stops at the end of the second asymmetric period t3. During the operation of the device, the user can feel weak electrical stimulation, heat compress and mechanical vibration in the nose and corners of the eyes. The programmable control App can be used to wirelessly upgrade the firmware program of the wearable therapeutic device over the air, and the power management unit 50 is used to charge and discharge the built-in rechargeable battery and generate and monitor and protect various potentials required for circuit operation.

[0057] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A wearable device for treating eye diseases, characterized in that: It includes a nasal root and trochlear nerve stimulation unit, an ethmoid sinus and turbinate thermal auxiliary unit, a vibration unit, a bending hinge unit, a power management unit and a wireless signal transmission unit, among which: The nasal root and trochlear nerve stimulation units are provided with at least two groups, which are electric pulse generating devices that output electric stimulation signals, and the surface material is conductive gel; The ethmoid sinus and turbinate heat auxiliary units are provided with at least two groups, the positions of which overlap or partially overlap with the nasion and trochlear nerve stimulation units, and include heat-conducting components; The vibration units are provided with at least two groups, outputting vibrations with preset frequencies and vibration amplitudes; The bending hinge unit is arranged at the central position of the entire wearable device, and the bending hinge unit can be adapted according to the width and curvature of the user's nose; The power management unit includes a power manager and a rechargeable battery, and the power manager manages the charging and discharging of the rechargeable battery, generates the potential required for the stimulation unit to work, and manages energy recovery; The wireless signal transmission unit is distributed around the bending hinge unit, receives program control parameters, and can receive remote commands, including opening or closing, parameter adjustment, mode configuration, program air upgrade and power acquisition; The high-voltage power supply in the nasal root and trochlear nerve stimulation unit is boosted from a 3V DC low voltage to a 30V pulsating voltage through a variable PWM controlled LC, and then boosted to 100V or above through a backup voltage circuit formed by a cascaded diode and capacitor. The front and rear stages of the high-voltage power supply circuit are electrically isolated to perform energy and signal isolation transmission, and have an electrical isolation characteristic of 3000V or above; The nasal root and trochlear nerve stimulation unit generates 2K-10K medium frequency carrier electric pulses modulated at a low frequency of 1-200 Hz, and the modulated pulses are symmetrical in the initial state, asymmetrical in the intermediate state, and symmetrical in the final state; The stimulation and regulation method of the nasal root and trochlear nerve stimulation unit is divided into four stages: t1, t2, t3, and t4: In the t1 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t1 treatment stage, the treatment pulse amplitude returns to zero; In the t2 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is greater than the positive pulse amplitude. The thermal auxiliary function can be set in the t2 treatment stage, and the thermal auxiliary intensity is controlled by the proportional coefficient; In the t3 treatment stage, the negative treatment pulse and the positive treatment pulse are not equal in amplitude, and the absolute value of the negative pulse amplitude is smaller than the positive pulse amplitude. The vibration function can be set in the t3 treatment stage, and the vibration intensity is related to the vibration frequency and vibration amplitude; In the t4 treatment stage, the treatment negative pulse and the treatment positive pulse are of equal amplitude, and the negative pulse and the positive pulse are output alternately. At the end of the t4 treatment stage, the treatment pulse amplitude returns to zero.

2. The wearable device for treating eye diseases according to claim 1, characterized in that: The ethmoid sinus and turbinate thermal auxiliary unit comprises a flexible carbon nanotube film, a thin copper sheet and a thermal insulation layer arranged in sequence, wherein the flexible carbon nanotube film is adjacent to the nasal root and trochlear nerve stimulation unit.

3. The wearable device for treating eye diseases according to claim 1, characterized in that: The vibration unit includes a transverse linear motor or a micro piezoelectric vibration piece or a mechanical vibration motor.

4. The wearable device for treating eye diseases according to claim 1, characterized in that: The vibration frequency of the vibration unit is 10-60 Hz, and the vibration stroke is 0.1 mm-1 mm.

5. The wearable device for treating eye diseases according to claim 1, characterized in that: The bending hinge unit includes a first chain shaft, a second chain shaft, a third chain shaft, a micro chain rod, a horizontal axis limit point and a torque spring, wherein the first chain shaft and the second chain shaft are arranged at intervals, and the horizontal axis limit point is set on the third chain shaft. The torque area is an area where a torque spring is provided. Torque springs are distributed on the first chain shaft and the second chain shaft in the torque area. The first chain shaft and the second chain shaft drive the torque spring to generate a torque distribution, and the torque distribution is different according to the different activity angles of different parts of the chain shaft. Once the torque is generated, the current torque value will be maintained to maintain the deformation state of the torque spring. The torque springs in the first chain shaft and the second chain shaft drive the third chain shaft to generate a bulge angle, and the third chain shafts adjacent to each other overlap to form a bulge. The horizontal axis limit point on the third chain shaft touches the second chain shaft after the third chain shaft reversely moves to a preset stroke and cannot move anymore. The bending hinge unit is prevented from reverse bending through the horizontal axis limit point, that is, it cannot form a concave shape.

Images